N Matsumoto

Kyoto Prefectural University of Medicine, Kioto, Kyōto, Japan

Are you N Matsumoto?

Claim your profile

Publications (8)17.63 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the present study was to clarify whether bile acids influence chemiluminescence (CL) in the liver in vivo. Hepatic CL was determined on the surface of the liver of anaesthetized rats by using a photon counter. In normal rats, hepatic CL was significantly decreased 30 min after enteral administration of chenodeoxycholic acid (CDCA) or deoxycholic acid (DCA), but returned to its initial level 3 h later, after part of the CDCA administered was metabolized. Ursodeoxycholic acid (UDCA) and cholic acid had no effect on CL. In contrast, hepatic CL was markedly increased 30 min after CDCA or DCA administration in rats given either buthionine sulphoximine (BSO), an inhibitor of γ-glutamylcysteine synthetase, or diethyldithiocarbamate (DDC), an inhibitor of both superoxide dismutase and glutathione peroxidase. Chenodeoxycholic acid further increased the CL of BSO- or DDC-treated rats during inhalation of oxygen via a tracheal cannula. Coadministration of UDCA eliminated the effects of CDCA on the hepatic CL of normal and BSO- or DDC-treated rats with or without oxygen inhalation. We conclude that cytotoxic bile acids, such as CDCA, increase CL in the antioxidants-depleted or oxidative-stressed liver in vivc, but that UDCA prevents CDCA from developing CL.
    Journal of Gastroenterology and Hepatology 06/2008; 13(1):81 - 87. · 3.33 Impact Factor
  • T Nakashima, N Matsumoto, K Kashima
    [Show abstract] [Hide abstract]
    ABSTRACT: The interactions between bovine gallstones (Goou) and bear gall powder (Yutan) in decreases in serum transaminase levels were investigated in rats intoxicated with carbon tetrachloride (CCl4). The p.o. administration of Goou significantly increased both serum transaminase levels and hepatic lipid peroxidation following i.p. administration of CCl4. Concomitant administration of both Goou and Yutan resulted in decreases of serum transaminase levels and hepatic lipid peroxidation, which were more remarkable than with administration of Yutan alone. Goou significantly increased the estimated hepatic blood flow in the indocyanine green clearance test and enhanced the delivery of CCl4 to the liver from the peritoneal cavity. These findings suggest that Goou exacerbates CCl4-induced hepatic damage because of the accelerated delivery of CCl4 to the liver and that Goou might have a hemodynamic drug interaction with Yutan in the liver, possibly enhancing the hepatoprotective effect of Yutan.
    The Japanese Journal of Pharmacology 04/1998; 76(3):271-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the present study was to clarify whether bile acids influence chemiluminescence (CL) in the liver in vivo. Hepatic CL was determined on the surface of the liver of anaesthetized rats by using a photon counter. In normal rats, hepatic CL was significantly decreased 30 min after enteral administration of chenodeoxycholic acid (CDCA) or deoxycholic acid (DCA), but returned to its initial level 3 h later, after part of the CDCA administered was metabolized. Ursodeoxycholic acid (UDCA) and cholic acid had no effect on CL. In contrast, hepatic CL was markedly increased 30 min after CDCA or DCA administration in rats given either buthionine sulphoximine (BSO), an inhibitor of gamma-glutamylcysteine synthetase, or diethyldithiocarbamate (DDC), an inhibitor of both superoxide dismutase and glutathione peroxidase. Chenodeoxycholic acid further increased the CL of BSO- or DDC-treated rats during inhalation of oxygen via a tracheal cannula. Coadministration of UDCA eliminated the effects of CDCA on the hepatic CL of normal and BSO- or DDC-treated rats with or without oxygen inhalation. We conclude that cytotoxic bile acids, such as CDCA, increase CL in the antioxidants-depleted or oxidative-stressed liver in vivo, but that UDCA prevents CDCA from developing CL.
    Journal of Gastroenterology and Hepatology 02/1998; 13(1):81-7. · 3.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine the actions of taurine and calcium on biological membranes, the effects of these compounds on the mobility of phospholipids of resealed and sonicated ghosts of human erythrocytes were investigated, using 31P-NMR spectroscopy. In addition, the effects of taurine and calcium on lipid fluidity were investigated by ESR spectroscopy, using a spin-labeling method with 5-doxyl stearic acid. The mobility of the membranes decreased following treatment with 10 mM taurine, but coadministration of 2.5 mM calcium blocked this effect. The fluidity of the membranes was not changed following treatment with 10 mM taurine, but decreased following coadministration of 2.5 mM calcium. These actions of taurine and calcium on the dynamics of biological membranes might explain, in part, the observation that most of the pharmacological effects of taurine on mammalian organs occur in the presence of calcium ions.
    Biochemical Pharmacology 08/1996; · 4.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine the actions of taurine and calcium on biological membranes, the effects of these compounds on the mobility of phospholipids of resealed and sonicated ghosts of human erythrocytes were investigated, using 31P-NMR spectroscopy. In addition, the effects of taurine and calcium on lipid fluidity were investigated by ESR spectroscopy, using a spin-labeling method with 5-doxyl stearic acid. The mobility of the membranes decreased following treatment with 10 mM taurine, but coadministration of 2.5 mM calcium blocked this effect. The fluidity of the membranes was not changed following treatment with 10 mM taurine, but decreased following coadministration of 2.5 mM calcium. These actions of taurine and calcium on the dynamics of biological membranes might explain, in part, the observation that most of the pharmacological effects of taurine on mammalian organs occur in the presence of calcium ions.
    Biochemical Pharmacology 07/1996; 52(1):173-176. · 4.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: 1. Taurine had cytoprotective effects on hepatocytes under hyperoxic or hypoxic condition in the presence of Ca2+. 2. Bile acids had toxic effects on hepatocytes; there was no significant difference in the toxicity between free bile acids and taurine-conjugated bile acids. 3. The mobility of the membranes, examined by 31P-NMR, decreased after treatment with taurine or free bile acids, but increased after treatment with taurine-conjugated bile acids. 4. The fluidity of the membranes, measured by ESR, did not change after treatment with taurine, but decreased after treatment with free bile acids and increased after treatment with taurine-conjugated bile acids. In conclusion, because most bile acids are conjugated with taurine in the liver after administration of taurine, the influence of taurine-conjugated bile acids has to be taken into consideration in estimating the functions of taurine in the liver.
    Advances in experimental medicine and biology 02/1996; 403:85-92. · 1.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The effects of ursodeoxycholic acid (UDCA) on the liver function test values were investigated in patients with chronic hepatitis (CH) and liver cirrhosis (LC) in whom treatment with glycyrrhizin (SNMC) for more than 6 months had failed to improve serum transaminase levels. Twenty-six patients treated with Stronger neo minophagen C (SNMC), 60 ml, i.v., three times/week) for more than 6 months were given UDCA (Urso, 600 mg/day) in addition (SNMC + UDCA group) and 22 patients were given UDCA (Urso, 600 mg/day) alone (UDCA group). The mean AST, ALT, γ-GTP and total bile acid (TBA) values during the 3 months before UDCA treatment and the 3 months after the start of UDCA treatment were compared in each case. The results showed that AST, ALT and γ-GTP were improved by 28, 34 and 46%, respectively in the 24 patients with CH, type C in the SNMC + UDCA group, and 27, 30 and 39%, respectively in the 14 patients with CH, type C in the UDCA group. UDCA was also effective in improving AST and ALT in the patients in the SNMC + UDCA group who were resistant to interferon therapy. The percentages of improvement in AST, ALT and γ-GTP in the 10 LC patients were lower than in the CH patients in both SNMC + UDCA and UDCA group. In conclusion, UDCA is useful in decreasing the serum transaminase levels of patients with CH, even when they are being treated with SNMC.
    International Hepatology Communications 01/1996;
  • N Matsumoto, T Nakashima, K Kashima
    [Show abstract] [Hide abstract]
    ABSTRACT: The author reports 23 cases of chronic liver disease which showed remarkable improvement with the administration of bovine gallstone (Goou) and bear gall powder (Yutan). The concomitant administration of both Goou at 200 mg/day and Yutan at 60 mg/day resulted in marked improvement of liver function as well as subjective complaints in all the patients within one month. The administration of Goou alone was also effective, but concomitant administration of Goou and Yutan tended to be more effective than administration of Goou alone in cases of liver cirrhosis. These results suggest that animal crude drugs (Goou and Yutan) are reliable medicines for intractable chronic liver diseases.
    The Tokai journal of experimental and clinical medicine 06/1995; 20(1):9-16.